A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.


Kayaaslan B., Akinci E., Ari A., Tufan Z. , Alpat S. N. , Gunal O., et al.

Clinics and research in hepatology and gastroenterology, cilt.42, ss.40-47, 2018 (SCI Expanded İndekslerine Giren Dergi)

  • Cilt numarası: 42 Konu: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.clinre.2017.06.008
  • Dergi Adı: Clinics and research in hepatology and gastroenterology
  • Sayfa Sayısı: ss.40-47

Özet

Background: Entecavir (ETV) and tenofovir disoproxil fumarat (TDF) are the two first-line therapies recommended in the treatment of chronic hepatitis B because of having potent antiviral effect and high genetic barriers against resistance. We aimed to compare efficacy of these drugs and to evaluate predictors of viral suppression.